From Trials to Clinics: Considerations for Implementing Psychedelic‐Assisted Therapy Into Clinical Practice
Jessie Kim, Liam Lochhead, Cory R. Weissman
Pharmacology Research & Perspectives May 10, 2026 DOI: 10.1002/prp2.70262 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Legalization Clinical trial Mainstream Inclusion mineral Fidelity Openness to experience Protocol science Compassionate use Psychotherapist Neglect Best practice Rigour Medline Good clinical practice Standardization Critical appraisal |
Abstract
Interest in psychedelic-assisted therapy (PAT) is surging across research and medical communities, prompting the discussion of policy shifts that reflect growing openness to implementing psychedelics in clinical practice. State-level psychedelic reform in the United States has accelerated since 2019, with legalization projected to reach most states within the next decade if trends follow those of cannabis [1]. This transition of PAT from tightly controlled clinical trials to real-world practice raises concerns about how patient screening, treatment setting, and therapist support will be managed outside research environments.
Citations in the library
Cites 14
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psychedelics and the essential importance of context. Journal of Psychopharmacology February 15, 2018
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Psychedelic integration: An analysis of the concept and its practice Frontiers in Psychology August 4, 2022
- Ketamine treatment for depression: a review Discover Mental Health April 15, 2022
and 9 more in the library